Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype

L Lauren Merz (5Dana-Farber Cancer Institute, Medical Oncology, Boston, United States) G Gilles Attipoe (4St. Peter's University Hospital, New Brunswick, United States) C Christina Barriteau (5Lurie Children's Hospital, Chicago, United States) M Michael Blechner (6University of Connecticut, Farmington, United States) E Eric Burks (1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, United States) C Cecelia Calhoun (3Yale School of Medicine, Pediatrics, New Haven, United States) S Sally Campbell Lee (9University of Illinois Chicago, Chicago, United States) V Vivian Chang (3University of California Los Angeles Health, Los Angeles, United States) S Stella Chou (2Children's Hospital of Philadelphia, Pediatrics, Philadelphia, United States) A Adam Cuker (3Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States) E Emmanuel Fadeyi (13Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, United States) W Warren Fingrut (1MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States) V Victoria Forbes (2University of Connecticut, Hematology and Oncology, Farmington, United States) I Ivo Francischetti (15Johns Hopkins University Hospital, Baltimore, United States) V Vijayakrishna Gadi (9University of Illinois Chicago, Chicago, United States) R Richard Godby (1Mayo Clinic, Department of Internal Medicine, Rochester, United States) L Lucy Godley (4Northwestern University, Chicago, United States) A Abraham Haimed (11Children's Hospital of Philadelphia, Philadelphia, United States) H Hyojeong Han (Department of Biomedical Engineering, Hanyang University) R Richard Haspel (19Beth Israel Deaconess Hospital, Boston, United States) C Chibuzo Ilonze (1University of Alabama at Birmingham, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Heersink School of Medicine, Birmingham, United States) C Cyril Jacquot (18Children's National Hospital, Washington, D.C., United States) P Peng Ji J Justin Juskewitch (16Mayo Clinic, Rochester, United States) M Matthew Karafin (1University of North Carolina at Chapel Hill, Pathology and Laboratory Medicine, Chapel Hill, United States) K Kimberly Klein (14The University of Texas MD Anderson Cancer Center, Houston, United States) N Nicole Kucine (14Department of Pediatrics, Weill Cornell Medicine, New York, United States) P Priya Kumar M Margarita Kushnir (24Banner Health, Phoenix, United States) D David Levitz (1Montefiore Einstein Comprehensive Cancer Center, Bronx, United States) M Michael Lewis G Geling Li (20University of Alabama at Birmingham, Birmingham, United States) Z Zhen Mei (10University of California Los Angeles, Los Angeles, United States) S Sabrina Racine Brzostek (6Weill-Cornell Medical College, Medicine, New York City, United States) G Gary Rose (26Nemours Children's Hospital, Wilmington, United States) C Corinna Schultz (26Nemours Children's Hospital, Wilmington, United States) A Alexa Siddon C Christine Sillings (27Norton Healthcare, Louisville, United States) J John Mark Sloan (2Boston Medical Center, Boston, United States) A Amy Soni (13Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, United States) D Don Stevens (3Norton Cancer Institute, Louisville, United States) C Charlotte Story (1Johns Hopkins University School of Medicine, Division of Hematology, Department of Medicine, Baltimore, United States) J James Szymanski (25Montefiore Medical Center and Albert Einstein College of Medicine, New York City, United States) C Clifford Takemoto (21St. Jude Children's Research Hospital, Memphis, United States) A Alexis Thompson R Rahma Warsame (1Mayo Clinic, Rochester, United States) A Angela Weyand (4Department of Pediatrics, University of Michigan Medical School, Ann Arbor, United States) S Samuel Wilson N Nibal Zaghloul (4St. Peter's University Hospital, New Brunswick, United States) Y Yadashe Belay (28American Society of Hematology, Washington, D.C., United States) A Aliza Fink (8National Organization for Rare Disorders, Quincy, United States) P Patricia Frustace (28American Society of Hematology, Washington, D.C., United States) J Jamie Tyson (28American Society of Hematology, Washington, D.C., United States) N Nathalie Van Havre (1American Society of Hematology, Washington, United States) M Maureen Okam Achebe (17Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA)

Abstract

Abstract Introduction: The Duffy null variant (genotype or phenotype) is associated with lower circulating absolute neutrophil counts (ANC) without increased risk for infection. It is found in ~66% of people identifying as Black or African American vs <1% of people of Asian or European ancestry. Many ANC reference intervals (RI) are not representative of the Duffy null population. There are no adult Duffy null WBC RI and no pediatric Duffy null ANC or WBC RI. Thus, we aimed to assess Duffy null ANC and WBC distributions as well as develop WBC and ANC RI for adults and pediatrics. Methods: Twenty-three sites across the United States collected samples with all sites excluding participants with conditions or medications that could impact ANC or WBC. Only Duffy null participants were included. Sex, race, ethnicity, age, sample collection type, practice setting, Duffy testing method, ANC, and WBC were recorded. The non-parametric method for determining lower limit of normal (LLN), upper limit of normal (ULN), and 90% confidence intervals (CI) around the limits was performed according to the Clinical and Laboratory Standards Institute guidelines. Specific ULN and LLN are not reported as these are preliminary data. The Mann-Whitney U test was used to compare sex and prior data; differences by age groups were assessed with Kruskal-Wallis test. Results: 316 participants 18+ years-old (y/o) were assessed of whom 62.3% (n=197) are female, 97.5% (n=308) identified as Black or African American, and 94.9% (n=300) identified as non-Hispanic. Median age was 47 y/o (IQR: 32-60.5). Median ANC was 2600/uL (IQR: 1860-3530; range: 400-7400); 28.6% (n=90) of participants had ANC <2000/uL, 13.6% (n=43) had ANC <1500/uL, and 2.5% (n=8) had <1000/uL. The 90% CI around the LLN was 810-1070/uL and 5570-7130/uL around the ULN. Consistent with prior data, there was a difference in median ANC by sex (male: 2400/uL; female: 2710/uL; p=0.02). There was no significant difference between this ANC data and previously published Duffy null ANC data (p=0.28). Median WBC was 5.4x109/L (IQR: 4.4-6.5; range: 2.10-11.64) with 4.1% (n=13) of participants with WBC <3.0x109/L. The 90% CI around the LLN is 3.68-4.30x109/L and 11.02-12.97x109/L around the ULN. 515 participants between 0-17 y/o were assessed with 51.8% (n=267) females, 94.8% (n=488) identified as Black or African American, and 94.0% (n=484) identified as non-Hispanic. Among pediatric participants, 56.8% (n=291) had ANC <2000/uL, 38.7% (n=198) had ANC <1500/uL, and 14.4% (n=74) had ANC <1000/uL. For those <1 y/o (n=29), median ANC was 950/uL (IQR: 840-1360; range: 111-3910). There are currently too few samples to predict ULN and LLN. Median WBC was 8.85x109/L (IQR: 7.03-10.16; range: 4.17-13.53). For those 1-5 y/o (n=143), median ANC was 1735/uL (IQR: 1100-2550; range: 207-5810) with a 90% CI around the LLN of 207-820/uL and 4020-5810/uL around the ULN. Median WBC was 6.72x109/L (IQR: 5.64-8.25; range: 3.68-12.97). For those 6-11 y/o (n=128), median ANC was 1590/uL (IQR: 1090-2470; range: 420-5490) with a 90% CI around the LLN of 420-910/uL and 4340-5490/uL around the ULN. Median WBC was 5.42x109/L (IQR: 4.45-6.70; range: 2.80-10.50). For those 12-17 y/o (n=215), median ANC was 2190/uL (IQR: 1460-2930; range: 204-5850) with a 90% CI around the LLN of 540-930/uL and 4350-5510/uL around the ULN. Median WBC was 5.06x109/L (IQR: 4.26-6.20; range of 2.04-9.91). There is a significant difference in ANC by age category (p<0.0001). Conclusion: This is the first report of healthy pediatric Duffy null ANC and WBC data and the first large-scale verification of adult Duffy null ANC and WBC data. Final RI are expected in September 2025. Among adults with the Duffy null phenotype, ANC LLN are likely between 810-1070/uL. Pediatric ANC LLN are likely as low as 207-820/uL (1-5 y/o), 420-910/uL (6-11 y/o), and 540-930/uL (12-17 y/o). These findings redefine “normal” as a significant proportion of healthy participants have ANC or WBC below current RI or below thresholds typically defined as disease. Limitations include heterogeneous sample populations and collection methods. Future analyses will assess differences between collection sites or methods. Ultimately, this work lays the foundation for a more scientifically sound and equitable approach to medical care by ensuring that RI accurately reflects health for the entire community. Healthcare systems are strongly encouraged to adopt Duffy null-specific ANC and WBC RI.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 1074-1074
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (55)

L

Lauren Merz

5Dana-Farber Cancer Institute, Medical Oncology, Boston, United States

G

Gilles Attipoe

4St. Peter's University Hospital, New Brunswick, United States

C

Christina Barriteau

5Lurie Children's Hospital, Chicago, United States

M

Michael Blechner

6University of Connecticut, Farmington, United States

E

Eric Burks

1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, United States

C

Cecelia Calhoun

3Yale School of Medicine, Pediatrics, New Haven, United States

S

Sally Campbell Lee

9University of Illinois Chicago, Chicago, United States

V

Vivian Chang

3University of California Los Angeles Health, Los Angeles, United States

S

Stella Chou

2Children's Hospital of Philadelphia, Pediatrics, Philadelphia, United States

A

Adam Cuker

3Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States

E

Emmanuel Fadeyi

13Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, United States

W

Warren Fingrut

1MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States

V

Victoria Forbes

2University of Connecticut, Hematology and Oncology, Farmington, United States

I

Ivo Francischetti

15Johns Hopkins University Hospital, Baltimore, United States

V

Vijayakrishna Gadi

9University of Illinois Chicago, Chicago, United States

R

Richard Godby

1Mayo Clinic, Department of Internal Medicine, Rochester, United States

L

Lucy Godley

4Northwestern University, Chicago, United States

A

Abraham Haimed

11Children's Hospital of Philadelphia, Philadelphia, United States

H

Hyojeong Han

Department of Biomedical Engineering, Hanyang University

R

Richard Haspel

19Beth Israel Deaconess Hospital, Boston, United States

C

Chibuzo Ilonze

1University of Alabama at Birmingham, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Heersink School of Medicine, Birmingham, United States

C

Cyril Jacquot

18Children's National Hospital, Washington, D.C., United States

P

Peng Ji

J

Justin Juskewitch

16Mayo Clinic, Rochester, United States

M

Matthew Karafin

1University of North Carolina at Chapel Hill, Pathology and Laboratory Medicine, Chapel Hill, United States

K

Kimberly Klein

14The University of Texas MD Anderson Cancer Center, Houston, United States

N

Nicole Kucine

14Department of Pediatrics, Weill Cornell Medicine, New York, United States

P

Priya Kumar

M

Margarita Kushnir

24Banner Health, Phoenix, United States

D

David Levitz

1Montefiore Einstein Comprehensive Cancer Center, Bronx, United States

M

Michael Lewis

G

Geling Li

20University of Alabama at Birmingham, Birmingham, United States

Z

Zhen Mei

10University of California Los Angeles, Los Angeles, United States

S

Sabrina Racine Brzostek

6Weill-Cornell Medical College, Medicine, New York City, United States

G

Gary Rose

26Nemours Children's Hospital, Wilmington, United States

C

Corinna Schultz

26Nemours Children's Hospital, Wilmington, United States

A

Alexa Siddon

C

Christine Sillings

27Norton Healthcare, Louisville, United States

J

John Mark Sloan

2Boston Medical Center, Boston, United States

A

Amy Soni

13Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, United States

D

Don Stevens

3Norton Cancer Institute, Louisville, United States

C

Charlotte Story

1Johns Hopkins University School of Medicine, Division of Hematology, Department of Medicine, Baltimore, United States

J

James Szymanski

25Montefiore Medical Center and Albert Einstein College of Medicine, New York City, United States

C

Clifford Takemoto

21St. Jude Children's Research Hospital, Memphis, United States

A

Alexis Thompson

R

Rahma Warsame

1Mayo Clinic, Rochester, United States

A

Angela Weyand

4Department of Pediatrics, University of Michigan Medical School, Ann Arbor, United States

S

Samuel Wilson

N

Nibal Zaghloul

4St. Peter's University Hospital, New Brunswick, United States

Y

Yadashe Belay

28American Society of Hematology, Washington, D.C., United States

A

Aliza Fink

8National Organization for Rare Disorders, Quincy, United States

P

Patricia Frustace

28American Society of Hematology, Washington, D.C., United States

J

Jamie Tyson

28American Society of Hematology, Washington, D.C., United States

N

Nathalie Van Havre

1American Society of Hematology, Washington, United States

M

Maureen Okam Achebe

17Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA